Impact of elevated left ventricular filling pressure on long-term outcomes after transcatheter aortic valve replacement.
heart failure, diastolic
heart valve diseases
transcatheter aortic valve replacement
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
09
03
2022
accepted:
11
05
2022
entrez:
21
6
2022
pubmed:
22
6
2022
medline:
24
6
2022
Statut:
ppublish
Résumé
Increase in left ventricular filling pressure (FP) and diastolic dysfunction are established consequences of progressive aortic stenosis (AS). However, the impact of elevated FP as detected by pretranscatheter aortic valve replacement (TAVR) echocardiogram on long-term outcomes after TAVR remains unclear. To understand the impact of elevated FP in patients with severe AS who undergo TAVR. This was a retrospective study of all patients who underwent TAVR between 1 January 2014 and 31 December 2017. The presence of elevated FP was determined in accordance with the latest guidelines using the last available comprehensive echocardiogram prior to TAVR. Of 983 patients who were included in our study, 422 patients (43%) were found to have elevated FP and 561 patients (57%) had normal FP prior to TAVR. Patients with elevated FP had a mean age of 81.2±8.6 years and were more likely to be males (62%), diabetic (41% vs 35%, p=0.046), and have a higher prevalence of atrial fibrillation (Afib) (53% vs 39%, p<0.001). The 5-year all-cause mortality after TAVR was significantly higher in patients with elevated FP when compared with patients with normal FP (32% vs 24%, p=0.006). The presence of elevated FP, history of Afib and prior PCI emerged as independent predictors of long-term mortality after TAVR. Elevated FP is associated with increased mortality in patients with severe AS undergoing TAVR. Assessment of FP should be incorporated into the risk assessment of AS patients to identify those who may benefit from early intervention.
Sections du résumé
BACKGROUND
Increase in left ventricular filling pressure (FP) and diastolic dysfunction are established consequences of progressive aortic stenosis (AS). However, the impact of elevated FP as detected by pretranscatheter aortic valve replacement (TAVR) echocardiogram on long-term outcomes after TAVR remains unclear.
OBJECTIVE
To understand the impact of elevated FP in patients with severe AS who undergo TAVR.
METHODS
This was a retrospective study of all patients who underwent TAVR between 1 January 2014 and 31 December 2017. The presence of elevated FP was determined in accordance with the latest guidelines using the last available comprehensive echocardiogram prior to TAVR.
RESULTS
Of 983 patients who were included in our study, 422 patients (43%) were found to have elevated FP and 561 patients (57%) had normal FP prior to TAVR. Patients with elevated FP had a mean age of 81.2±8.6 years and were more likely to be males (62%), diabetic (41% vs 35%, p=0.046), and have a higher prevalence of atrial fibrillation (Afib) (53% vs 39%, p<0.001). The 5-year all-cause mortality after TAVR was significantly higher in patients with elevated FP when compared with patients with normal FP (32% vs 24%, p=0.006). The presence of elevated FP, history of Afib and prior PCI emerged as independent predictors of long-term mortality after TAVR.
CONCLUSION
Elevated FP is associated with increased mortality in patients with severe AS undergoing TAVR. Assessment of FP should be incorporated into the risk assessment of AS patients to identify those who may benefit from early intervention.
Identifiants
pubmed: 35728890
pii: openhrt-2022-002015
doi: 10.1136/openhrt-2022-002015
pmc: PMC9214428
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Am Coll Cardiol. 2020 Dec 22;76(25):2940-2951
pubmed: 33334422
Eur Heart J. 2020 Feb 21;41(8):943-954
pubmed: 31711153
Circulation. 1996 Nov 1;94(9):2138-45
pubmed: 8901664
Nat Rev Cardiol. 2011 Jun 14;8(9):494-501
pubmed: 21670747
Circ Cardiovasc Interv. 2013 Feb;6(1):77-84
pubmed: 23386662
Eur Heart J. 2012 Apr;33(7):904-12
pubmed: 21990265
Circulation. 2012 Nov 6;126(19):2353-62
pubmed: 23129702
Circulation. 2021 Feb 2;143(5):e35-e71
pubmed: 33332149
JACC Cardiovasc Interv. 2018 Mar 26;11(6):593-601
pubmed: 29501544
Am J Cardiol. 2017 Jun 1;119(11):1832-1838
pubmed: 28395888
Circulation. 1993 May;87(5 Suppl):IV73-6
pubmed: 8485837
Circulation. 1984 May;69(5):855-65
pubmed: 6231136
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Soc Echocardiogr. 2021 May;34(5):465-471
pubmed: 33388447
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
J Am Coll Cardiol. 2011 Apr 19;57(16):1650-7
pubmed: 21492762
J Am Soc Echocardiogr. 2000 Nov;13(11):980-5
pubmed: 11093099
Circulation. 1989 Apr;79(4):744-55
pubmed: 2522356
J Am Coll Cardiol. 2002 Dec 18;40(12):2182-8
pubmed: 12505232
JACC Cardiovasc Interv. 2016 May 9;9(9):937-46
pubmed: 27085579
JACC Cardiovasc Interv. 2019 Nov 11;12(21):2119-2129
pubmed: 31629743
Circulation. 2009 Jun 16;119(23):3009-16
pubmed: 19487594
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
Heart. 2015 Aug;101(16):1302-8
pubmed: 25972269